User menu

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.

Bibliographic reference Drach, Johannes ; Huang, Huiqiang ; Samoilova, Olga ; Belch, Andrew ; Farber, Charles ; et. al. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.. In: Leukemia and Lymphoma, (2018)
Permanent URL
  1. Herrmann Annina, Hoster Eva, Zwingers Thomas, Brittinger Günter, Engelhard Marianne, Meusers Peter, Reiser Marcel, Forstpointner Roswitha, Metzner Bernd, Peter Norma, Wörmann Bernhard, Trümper Lorenz, Pfreundschuh Michael, Einsele Hermann, Hiddemann Wolfgang, Unterhalt Michael, Dreyling Martin, Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma, 10.1200/jco.2008.16.8435
  2. Vose Julie M., Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management : Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series, 10.1002/ajh.23615
  3. Williams ME., Hematology Am Soc Hematol Educ Program, 2013, 568 (2013)
  4. Dreyling M., Geisler C., Hermine O., Kluin-Nelemans H. C., Le Gouill S., Rule S., Shpilberg O., Walewski J., Ladetto M., , Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 10.1093/annonc/mdu264
  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-cell Lymphomas. Version 3.2017; March 27, 2017. [cited 2017 Jun 23]. Available from:
  6. Pham L. V., Tamayo A. T., Yoshimura L. C., Lo P., Ford R. J., Inhibition of Constitutive NF- B Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis, 10.4049/jimmunol.171.1.88
  7. Chiarle R, Blood, 95, 619 (2000)
  8. Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for injection: for subcutaneous or intravenous use, full prescribing information. Version 19; June, 2017. [cited 2017 Jun 23]. Available from:
  9. Velcade. Summary of Product Characteristics. Last updated 10 March, 2017. [cited 2017 Jun 23]. Available from:
  10. Perez-Galan P., The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status, 10.1182/blood-2005-05-2091
  11. Robak Tadeusz, Huang Huiqiang, Jin Jie, Zhu Jun, Liu Ting, Samoilova Olga, Pylypenko Halyna, Verhoef Gregor, Siritanaratkul Noppadol, Osmanov Evgenii, Alexeeva Julia, Pereira Juliana, Drach Johannes, Mayer Jiri, Hong Xiaonan, Okamoto Rumiko, Pei Lixia, Rooney Brendan, van de Velde Helgi, Cavalli Franco, Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma, 10.1056/nejmoa1412096
  12. Giebel S., Labopin M., Ehninger G., Beelen D., Blaise D., Ganser A., Bacigalupo A., Czerw T., Holowiecki J., Fagundes E. M., Nowara E., Frassoni F., Rocha V., , Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia, 10.1182/blood-2010-01-266478
  13. Passweg J R, , Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R F, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M, Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually, 10.1038/bmt.2016.20
  14. Cheson Bruce D., Pfistner Beate, Juweid Malik E., Gascoyne Randy D., Specht Lena, Horning Sandra J., Coiffier Bertrand, Fisher Richard I., Hagenbeek Anton, Zucca Emanuele, Rosen Steven T., Stroobants Sigrid, Lister T. Andrew, Hoppe Richard T., Dreyling Martin, Tobinai Kensei, Vose Julie M., Connors Joseph M., Federico Massimo, Diehl Volker, Revised Response Criteria for Malignant Lymphoma, 10.1200/jco.2006.09.2403
  15. Flinn I. W., van der Jagt R., Kahl B. S., Wood P., Hawkins T. E., MacDonald D., Hertzberg M., Kwan Y.-L., Simpson D., Craig M., Kolibaba K., Issa S., Clementi R., Hallman D. M., Munteanu M., Chen L., Burke J. M., Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, 10.1182/blood-2013-11-531327
  16. Visco Carlo, Finotto Silvia, Zambello Renato, Paolini Rossella, Menin Andrea, Zanotti Roberta, Zaja Francesco, Semenzato Gianpietro, Pizzolo Giovanni, D'Amore Emanuele S.G., Rodeghiero Francesco, Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation, 10.1200/jco.2012.45.9842
  17. Inwards David J., Fishkin Paul A. S., Hillman David W., Brown David W., Ansell Stephen M., Kurtin Paul J., Fonseca Rafael, Morton Roscoe F., Veeder Michael H., Witzig Thomas E., Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group, 10.1002/cncr.23537
  18. Spurgeon Stephen E., Pindyck Talia, Okada Craig, Chen Yiyi, Chen Zunqiu, Mater Elana, Abbi Kamal, Epner Elliot M., Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma, 10.3109/10428194.2011.575489
  19. Ruan Jia, Martin Peter, Shah Bijal, Schuster Stephen J., Smith Sonali M., Furman Richard R., Christos Paul, Rodriguez Amelyn, Svoboda Jakub, Lewis Jessica, Katz Orel, Coleman Morton, Leonard John P., Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma, 10.1056/nejmoa1505237
  20. Fisher Richard I., Bernstein Steven H., Kahl Brad S., Djulbegovic Benjamin, Robertson Michael J., de Vos Sven, Epner Elliot, Krishnan Amrita, Leonard John P., Lonial Sagar, Stadtmauer Edward A., O'Connor Owen A., Shi Hongliang, Boral Anthony L., Goy André, Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma, 10.1200/jco.2006.07.9665
  21. Goy A., Bernstein S. H., Kahl B. S., Djulbegovic B., Robertson M. J., de Vos S., Epner E., Krishnan A., Leonard J. P., Lonial S., Nasta S., O'Connor O. A., Shi H., Boral A. L., Fisher R. I., Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study, 10.1093/annonc/mdn656
  22. Kane R. C., Dagher R., Farrell A., Ko C.-W., Sridhara R., Justice R., Pazdur R., Bortezomib for the Treatment of Mantle Cell Lymphoma, 10.1158/1078-0432.ccr-07-0871
  23. Romaguera Jorge E., Fayad Luis E., McLaughlin Peter, Pro Barbara, Rodriguez Alma, Wang Michael, Weaver Pamela, Hartig Kimberly, Kwak Larry W., Feldman Tatyana, Smith Judy, Ford Peggy, Goldberg Stuart, Pecora Andrew, Goy Andre, Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma : Bortezomid plus Intense Therapy in MCL, 10.1111/j.1365-2141.2010.08315.x
  24. Chang J. E., Li H., Smith M. R., Gascoyne R. D., Paietta E. M., Yang D. T., Advani R. H., Horning S. J., Kahl B. S., Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405), 10.1182/blood-2013-08-523845